H.C. Wainwright lowered the firm’s price target on Adaptimmune (ADAP) to $3.50 from $4 and keeps a Buy rating on the shares following the Q3 report.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAP: